Caudex, a division of McCann Complete Medical, is a global medical communications agency with over 25 years of industry experience, is well positioned to assist pharmaceutical firms with their education needs throughout the.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

XTALPI AND EDDC COLLABORATE IN AI-EMPOWERED DRUG DISCOVERY PROGRAM FOR NON-SMALL CELL LUNG CANCER

XtalPi Inc. | December 20, 2022

news image

XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced a strategic collaboration with the Experimental Drug Development Centre Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research of Singapore to discover novel treatment candidates for non-small cell lung cancer. Lung cancer is the second most common cancer and the leading cause of cancer death wor...

Read More

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc | October 07, 2020

news image

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

Read More

Pharmacy Market

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

news image

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More

Business Insights, PHARMA TECH

SIMULATIONS PLUS ENTERS NEW STRATEGIC COLLABORATION TO DISCOVER ANTICANCER THERAPIES THROUGH ITS AI-DRIVEN DRUG DESIGN TECHNOLOGY

Businesswire | March 29, 2023

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American Cancer Foundation (SACF). This collaboration will leverage Simulations Plus’ staff and Artificial Intelligence-driven Drug Design technology in the ADMET Predictor® software platform to support the discovery and design of novel inhibitors of methylenetetrahyd...

Read More
news image

Business Insights, PHARMACY MARKET

XTALPI AND EDDC COLLABORATE IN AI-EMPOWERED DRUG DISCOVERY PROGRAM FOR NON-SMALL CELL LUNG CANCER

XtalPi Inc. | December 20, 2022

XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced a strategic collaboration with the Experimental Drug Development Centre Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research of Singapore to discover novel treatment candidates for non-small cell lung cancer. Lung cancer is the second most common cancer and the leading cause of cancer death wor...

Read More
news image

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc | October 07, 2020

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

Read More
news image

Pharmacy Market

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More
news image

Business Insights, PHARMA TECH

SIMULATIONS PLUS ENTERS NEW STRATEGIC COLLABORATION TO DISCOVER ANTICANCER THERAPIES THROUGH ITS AI-DRIVEN DRUG DESIGN TECHNOLOGY

Businesswire | March 29, 2023

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American Cancer Foundation (SACF). This collaboration will leverage Simulations Plus’ staff and Artificial Intelligence-driven Drug Design technology in the ADMET Predictor® software platform to support the discovery and design of novel inhibitors of methylenetetrahyd...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us